[Frontiers in Bioscience E5, 141-153, January 1, 2013]

PET/CT in the imaging of ovarian Cancer

Owen J. O'Connor1, Priyanka Prakash2, Carmel G. Cronin1, Shaunagh McDermott1 and Michael A. Blake1

1Department of Radiology, Massachusetts General Hospital and Harvard Medical School, 55 Fruit St., Boston, MA 02114, USA, 2Department of Radiology, University of Pennsylvania, 3400 Spruce St., Philadelphia, PA, USA

TABLE OF CONTENTS

1. Abstract
2. Introduction
3. FDG PET/CT technique
4. FDG PET/CT imaging appearances
4.1. Distinguishing physiologic from pathologic increased ovarian FDG uptake
4.2 .Distinguishing benign versus malignant lesions
5. Staging of ovarian cancer
6. Detection of recurrent disease
7. Potential limitations
8. Conclusion
9. References

1. ABSTRACT

Ovarian cancer is responsible for the largest proportion of deaths among patients with gynecologic cancer. This paper discusses fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) in the imaging of ovarian cancer. We discuss and demonstrate how FDG PET/CT can be used to appropriately guide clinical management decisions in patients with ovarian cancer. In particular, FDG PET/CT shows great promise for the preoperative evaluation of women with primary ovarian cancer and for subsequent postoperative assessment for recurrence.